Zarrabian says namely, it expects to enroll its first glioblastoma multiforme (GBM) patient in a Phase 3 clinical trial using its lead compound VAL-083 by late 2020/early 2021.
Kintara expects to enroll first GBM patient in Phase 3 clinical trial by late 2020/early 2021
Quick facts: Kintara Therapeutics
Price: 1.71 USD
Market Cap: $52.37 m
NO INVESTMENT ADVICE
The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...
In exchange for publishing services rendered by the Company on behalf of Kintara Therapeutics named herein, including the promotion by the Company of Kintara Therapeutics in any Content on the Site, the Company...FOR OUR FULL DISCLAIMER CLICK HERE